Charles Fewlass

Trivalent Live Attenuated Intranasal Influenza Vaccine Administered During the 2003–2004 Influenza Type A (H3N2) Outbreak Provided Immediate, Direct, and Indirect Protection in Children

W. P. Glezen, P. Piedra, M. Gaglani, 2007, Pediatrics.

Safety of the Intranasal, Trivalent, Live Attenuated Influenza Vaccine (LAIV) in Children With Intermittent Wheezing in an Open-Label Field Trial

W. P. Glezen, P. Piedra, M. Gaglani, 2008, The Pediatric infectious disease journal.

Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004.

M. Halloran, I. Longini, P. Piedra, 2007, Vaccine.

Live Attenuated Influenza Vaccine, Trivalent, Is Safe in Healthy Children 18 Months to 4 Years, 5 to 9 Years, and 10 to 18 Years of Age in a Community-Based, Nonrandomized, Open-Label Trial

Pedro A Piedra, C. Hessel, P. Piedra, 2005, Pediatrics.

Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children.

Pedro A Piedra, C. Hessel, P. Piedra, 2005, Vaccine.

Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children.

M. Halloran, I. Longini, P. Piedra, 2004, Archives of pediatrics & adolescent medicine.